Company news
Krystal Biotech, Inc. (NASDAQ:KRYS) news
Krystal Biotech, Inc. news releases on 6ix. Latest, Jan 4, 2021: Krystal Biotech Appoints Dr. Chris Mason and Dr. Jing Marantz to its Board of Directors
Press releases — page 4
Krystal Biotech Appoints Dr. Chris Mason and Dr. Jing Marantz to its Board of Directors
January 3, 2021
Krystal Biotech to Present at the Evercore ISI HealthCONx Conference
November 23, 2020
Krystal Biotech Reports Third Quarter 2020 Financial Results and Provides Update on Operational Progress
November 8, 2020
Krystal Biotech Announces Departure of Chief Commercial Officer
October 15, 2020
Krystal Biotech to Present Pre-clinical Data Highlighting KB301 for Aesthetic Indications at the ASDS 2020 Virtual Meeting
October 7, 2020
Krystal Biotech to Present at HC Wainwright and Morgan Stanley Healthcare Conferences
September 8, 2020
Krystal Biotech Announces Initiation of Phase 1 Study Evaluating KB301 in Aesthetic Indications
August 24, 2020
Krystal Biotech’s KB407 Granted Orphan Drug Designation by the FDA to Treat Patients With Cystic Fibrosis
August 16, 2020
Krystal Biotech Reports Second Quarter 2020 Financial Results and Provides Update on Operational Progress
August 9, 2020
Krystal Biotech to Present at the William Blair BioTech Conference
July 29, 2020
Krystal Biotech Announces Initiation of Pivotal Phase 3 Study of Beremagene Geperpavec in Patients with Dystrophic Epidermolysis Bullosa
July 27, 2020
Krystal Biotech Appoints Whitney Ijem as Senior Vice President, Strategy and Business Development
July 19, 2020
Krystal Biotech to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
June 7, 2020
Krystal Biotech Announces Proposed Public Offering of Common Stock
May 17, 2020
Krystal Biotech Announces Pricing of $125 Million Public Offering of Common Stock
May 17, 2020
Krystal Biotech Announces Positive Interim Results from Phase 1/2 Clinical Trial of KB105 in Patients with TGM1-related Autosomal Recessive Congenital Ichthyosis (ARCI)
May 13, 2020
Krystal Biotech Reports First Quarter 2020 Financial Results and Provides Update on Operational Progress
May 3, 2020
Krystal Biotech Reports 2019 Financial Results and Business Progress
March 9, 2020
Krystal Biotech Announces Change in Financial Leadership
February 24, 2020
Krystal Biotech to Present at the Cowen 40th Annual Healthcare Conference
February 20, 2020
Krystal Biotech Breaks Ground On Second Commercial Gene Therapy Manufacturing Facility
January 23, 2020
Krystal Biotech Appoints Jennifer Chien as Chief Commercial Officer
January 20, 2020
Krystal Biotech to Present at the Piper Jaffray 31st Annual Healthcare Conference
November 25, 2019
Krystal Biotech Reports Third Quarter 2019 Financial and Operating Results
November 3, 2019
Krystal Biotech Announces Final Update from Phase 1/2 Clinical Trial of KB103 ("bercolagene telserpavec," "B-VEC")
October 28, 2019
Krystal Biotech Receives Positive EMA Opinion on Orphan Designation for KB105 to Treat Patients With TGM1 Deficient Autosomal Recessive Congenital Ichthyosis
October 9, 2019
Krystal Biotech to Present at the Cantor 2019 Global Healthcare Conference and Chardan's 3rd Annual Genetic Medicines Conference
September 29, 2019
Krystal Biotech Announces Granting of its First Foreign Patent and Reinforces its IP Portfolio with a New U.S. Patent
September 26, 2019